Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:


share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2020 | 09:35am EST

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today that it received the President's Award at the 8th Technology Management and Innovation Awards held by the Japan Techno-Economics Society (JATES).

The award was presented to Eisai for its discovery of the orally available kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) and its contributions towards patients with liver disease.

The Technology Management and Innovation Awards was established in 2012 with the aim of contributing to the development of Japan's economy, social transformation, and global competitiveness by introducing a wide range of outstanding innovations originating in Japan. This year marks the 8th anniversary of the award.

This award symbolizes high evaluation for Eisai's creation of the new treatment LENVIMA in Japan, the expedition of contributions towards patients through its strategic collaboration with Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) to globally co-develop and co-promote LENVIMA, and Eisai's efforts to support patients with liver disease based on its corporate philosophy.

LENVIMA was discovered at Eisai's Tsukuba Research Laboratories. It is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of proangiogenic pathway-related RTKs. Eisai obtained approval of manufacturing and marketing in Japan for LENVIMA indicated for the treatment of unresectable thyroid cancer in March 2015. In March 2018, LENVIMA received its first approval worldwide with additional indication for unresectable hepatocellular carcinoma (HCC) in Japan. LENVIMA thus became the first systemic therapy to be approved in Japan for front-line treatment of HCC in approximately 10 years. Eisai has also established its own liver disease support site to realize contributions to patients that cannot be achieved with drugs alone. The support site aims to help patients with hepatitis, cirrhosis, and liver cancer to resolve the anxiety they face in treatment and recuperation, as well as to foster a positive mindset towards treatment and an active lifestyle.

Eisai positions oncology as a key franchise area and aims to create innovative drugs that act towards healing cancer. In addition to innovation in drug development based on cutting-edge cancer research, Eisai aims to build an oncology ecosystem including prediction and prevention of cancer. Eisai will make continuous efforts to meet the diversified needs of, and increase the benefits provided to patients with cancer, their families, and healthcare professionals.

Institute founded in October 1966 to research technology, management, and economics and facilitate exchange among sectors thereof, to promote industrial activities (Japanese only): http://www.jates.or.jp/


Tel: +81-(0)3-3817-5120

LENVIMA, discovered and developed by Eisai, is a multiple receptor tyrosine kinase inhibitor (RTK) that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA also inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to normal cellular function, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFR), KIT, and RET.

In syngeneic mouse tumor models, LENVIMA decreased the tumor-associated macrophages population and increased the activated cytotoxic T cells population. LENVIMA demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone.

Currently, LENVIMA has been approved as a treatment for thyroid cancer in over 60 countries including Japan, the United States and in Europe; as a treatment for hepatocellular carcinoma in over 55 countries including Japan, the United States, in Europe, China, and in Asia; as well as in combination with everolimus as a treatment for renal cell carcinoma (second-line) in over 50 countries including the United States, in Europe, and in Asia. Additionally, it was also approved in the combination treatment of LENVIMA plus KEYTRUDA (generic name: pembrolizumab) for advanced endometrial carcinoma in the United States, Australia, and Canada. In Europe, the agent was launched under the brand name Kisplyx for renal cell carcinoma.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
02/24EISAI : Receives the president's award of the japan techno-economics society at ..
02/21Marriott Hires Former Merck CIO as Tech Chief
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
02/20Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation fo..
02/19Merck KGaA sells allergy unit to Dermapharm, keeps autoinjector project
02/19Merck KGaA Sells Allergy Business to Dermapharm
02/19MERCK AND : Receives Complete Response Letter from the US FDA for Supplemental B..
02/19Immutep Says Interim Phase II TACTI-002 Data Positive
02/18MERCK : Receives Complete Response Letter from the US FDA for Supplemental Biolo..
02/18Marriott Names Jim Scholefield Chief Information, Digital Officer
More news
Financials (USD)
Sales 2020 49 660 M
EBIT 2020 17 752 M
Net income 2020 12 422 M
Debt 2020 17 799 M
Yield 2020 2,97%
P/E ratio 2020 16,6x
P/E ratio 2021 15,5x
EV / Sales2020 4,53x
EV / Sales2021 4,18x
Capitalization 207 B
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 19
Average target price 98,11  $
Last Close Price 81,33  $
Spread / Highest target 31,6%
Spread / Average Target 20,6%
Spread / Lowest Target 10,7%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-10.58%207 065
JOHNSON & JOHNSON2.78%384 432
ROCHE HOLDING AG10.13%290 942
NOVARTIS2.72%211 608
PFIZER-8.83%191 868
NOVO NORDISK AS13.46%145 457